- In April 2023, Merck KGaA (Germany) announced the expansion of its reagent portfolio for cell lysis and dissociation applications, targeting both academic research and biopharmaceutical manufacturing. This strategic move is aimed at supporting high-throughput workflows and enhancing efficiency in nucleic acid and protein isolation, particularly in precision medicine and drug development sectors
- In March 2023, Thermo Fisher Scientific Inc. (U.S.) launched a next-generation mechanical dissociation system integrated with temperature control, designed for consistent processing of plant and mammalian tissues. The product aims to reduce sample variability and improve cell viability, reinforcing Thermo Fisher’s leadership in laboratory automation and molecular biology solutions
- In March 2023, Miltenyi Biotec (Germany) introduced a new enzymatic dissociation kit specifically optimized for delicate neural tissues. The kit is intended for use in neuroscience research and single-cell sequencing workflows, underlining the company’s focus on enabling high-yield, high-purity cell isolation from complex tissues
- In February 2023, Qsonica (U.S.) unveiled its upgraded ultrasonic cell disruptor equipped with enhanced amplitude control and real-time data logging. This new generation of instruments is designed to serve bioprocessing and microbiology labs requiring precision in bacterial and yeast cell lysis, thus improving reproducibility and throughput
- In January 2023, Bio-Rad Laboratories, Inc. (U.S.) partnered with multiple university research centers to validate its next-gen nucleic acid extraction kits that integrate both chemical and mechanical lysis technologies. The kits are engineered for downstream applications such as PCR, qPCR, and next-gen sequencing, supporting rapid diagnostic advancements and biomarker discovery initiatives
